Palisade Bio
PALI
10 hedge funds and large institutions have $388K invested in Palisade Bio in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
12% more capital invested
Capital invested by funds: $347K → $388K (+$40.3K)
11% more funds holding
Funds holding: 9 → 10 (+1)
0.19% more ownership
Funds ownership: 8.29% → 8.48% (+0.19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$184K |
| 2 |
AC
Armistice Capital
New York
|
+$140K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$26.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$23.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$29.1K |
| 2 |
Morgan Stanley
New York
|
-$350 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $174K | +$140K | +53,367 | +103% |
|
|
2
Cetera Investment Advisers
Schaumburg,
Illinois
| $116K | +$184K | +70,006 | New |
|
|
MG
3
Marex Group
London,
| $59K | – | – | – |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $16.6K | +$26.5K | +10,052 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $14.8K | +$23.5K | +8,943 | +28,848% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $7.73K | +$8.13K | +3,089 | +193% |
|
|
FDCDDQ
7
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $165 | – | – | – |
|
8
Wells Fargo
San Francisco,
California
| $35 | – | – | – |
|
9
Bank of America
Charlotte,
North Carolina
| $16 | +$3 | +1 | +11% |
|
|
10
Morgan Stanley
New York
| $12 | -$350 | -133 | -95% |
|
|
11
JP Morgan Chase
New York
| – | -$29.1K | -8,200 | Closed |
|
PALI Hedge Fund Activity: Q4 2024 in Review
10 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q4 2024, worth a combined $388K — up 12% from $347K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new PALI positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Cetera Investment Advisers, opening a new position worth an estimated $184K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $29.1K sold.
- 10 institutional investors held Palisade Bio (PALI) as of Q4 2024, up from 9 in Q3 2024.
- Funds reported $388K of Palisade Bio stock for Q4 2024, up 12% quarter-over-quarter.
- 2 funds opened new Palisade Bio positions in Q4 2024 and 1 closed out, a net change of +1 holder.
- The largest Palisade Bio buyer in Q4 2024 was Cetera Investment Advisers, an estimated $184K added.
- The largest Palisade Bio seller in Q4 2024 was JP Morgan Chase, an estimated $29.1K sold.
Based on aggregated 13F filings for Q4 2024.